Biotech Values

[rkrw]

AGIX.

I suppose ivus scans are quite complicated and apparently cumbersome to measure. I wouldn't know what renders a scan unreadable. I guess we'll have to see what the final cart II data show to see if they cherry picked in this interim analysis.

I think the bottom line for agix is the arise-events trial will be the new binary event and a HUGE one at that. Unless they agree to merge in the interim. Arise aftermath (up or down) will make cart II action seem insignificant.